Valuation: Paion AG

Market Cap 144K 166K 134K 124K 233K 15.82M 236K 1.58M 620K 7.92M 625K 611K 26.22M P/E 2021
-3.89x
P/E 2022 -53x
Enterprise Value 9.87M 11.39M 9.2M 8.46M 15.97M 1.08B 16.15M 108M 42.42M 542M 42.79M 41.84M 1.8B EV / Sales 2021
14.1x
EV / Sales 2022 1.22x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Manager TitleAgeSince
Chief Executive Officer 62 2023-08-31
Director of Finance/CFO - 2022-05-31
Director TitleAgeSince
Director/Board Member 65 2012-09-30
Director/Board Member 75 2017-05-31
Director/Board Member - 2019-05-21
Change 5-day change 1-year change 3-year change Capi.($)
-83.33%+10.77% - - 411K
+0.90%-2.33%+0.68%+14.52% 48B
+1.54%+8.40%+410.84%+561.64% 41.13B
+3.79%-4.54%+28.49%+7.76% 37.56B
+2.24%+0.89%+7.46%+76.05% 35.91B
+2.42%+7.27%+14.90%+44.79% 29.86B
+0.41%-2.85% - - 16.12B
+1.14%-0.47%+33.43%+123.57% 16.05B
+1.25%+1.52%+4.62%+18.66% 13.76B
+4.24%-8.04%-1.28%-34.87% 12.1B
Average +2.21%-2.15%+62.39%+101.52% 27.83B
Weighted average by Cap. +1.90%-1.29%+82.34%+127.89%

Financials

2021 2022
Net sales 7.13M 8.23M 6.64M 6.11M 11.54M 783M 11.67M 78.09M 30.65M 392M 30.91M 30.23M 1.3B 33.25M 38.39M 30.99M 28.51M 53.81M 3.65B 54.42M 364M 143M 1.83B 144M 141M 6.05B
Net income -21.79M -25.15M -20.31M -18.68M -35.26M -2.39B -35.66M -239M -93.66M -1.2B -94.47M -92.39M -3.96B -579K -669K -540K -496K -937K -63.57M -948K -6.34M -2.49M -31.81M -2.51M -2.46M -105M
Net Debt 13.77M 15.9M 12.84M 11.81M 22.29M 1.51B 22.54M 151M 59.2M 756M 59.71M 58.39M 2.51B 9.72M 11.23M 9.06M 8.34M 15.74M 1.07B 15.91M 107M 41.8M 534M 42.16M 41.23M 1.77B
Logo Paion AG
Paion AG is a Germany-based biopharmaceutical company. The Company's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The Company operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Employees
64